Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baricitinib
Study Locations (20)
Other
- Women's and Children's Hospital — Adelaide
- Box Hill Hospital — Box Hill
- Royal Brisbane and Women's Hospital — Brisbane
- Centre for Children's Health Research — Brisbane
- Royal Children's Hospital — Melbourne
- The Royal Melbourne Hospital — Parkville
- Perth Children's Hospital — Perth
- Sydney Children's Hospital — Randwick
- The Children's Hospital at Westmead — Westmead
- UZ Brussel — Brussels
- Cliniques universitaires Saint-Luc — Brussels
- Antwerp University Hospital — Edegem
- UZ Leuven — Leuven
Florida
- Tallahassee Memorial HealthCare — Tallahassee
- University of South Florida — Tampa
Iowa
- University of Iowa — Iowa City
- Iowa Diabetes and Endocrinology Research Center — West Des Moines
Kentucky
- Novak Center for Children's Health — Louisville
Pennsylvania
- Children's Hospital of Philadelphia (CHOP) — Philadelphia
Virginia
- University of Virginia — Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2031-07 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222137
The ClinicalTrials.gov registry entry for NCT07222137 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07222137 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Other, Florida, Iowa. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07222137 about?
NCT07222137 is a clinical study titled "A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults". The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
What is the current status of trial NCT07222137?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-01-12. Estimated completion is 2031-07.
What conditions does trial NCT07222137 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07222137?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07222137?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07222137 being conducted?
This trial has 20 study locations across Florida, Iowa, Kentucky, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.